Prescribing for Dry Eye Disease

The latest research points to a plethora of interventions

By: LISA HORNICK, OD, MBA, FAAO

Optometric Management July 16, 2025 Vol 60(6), Issue July/August 2025 Page(s): 18, 19, 20

Objective:

Emphasize the significance of the TFOS DEWS III report in shaping treatment options.

Key Findings:

Include specific examples of therapies for each driver.

Interpretation:

Mention implications for clinical practice.

Limitations:

Specify how the lack of clinical trial data affects treatment decisions.

Conclusion:

Reiterate the importance of individualized treatment plans.

Lisa Hornick

Specialties: Optometry

Bio: Lisa Hornick, OD, MBA, FAAO, is an optometrist whose published work in Optometric Management addresses dry eye disease treatment. Her writing focuses on clinical decision-making for dry eye disease, including targeted prescribing based on tear film deficiencies, eyelid abnormalities, and ocular surface abnormalities described in the TFOS DEWS III management and therapy algorithms.

PentaVision